NeuroSense Therapeutics is a late-stage clinical biotech company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases.

NeuroSense was founded in 2017 by Alon Ben-Noon, following a chance encounter with Shay Rishoni, a person living with ALS. Alon was inspired by Shay, who had served as the CEO of a non-profit organization for ALS. This pivotal meeting led Alon to team up with world-renowned scientists and biotech professionals to carry out research and develop an effective drug for ALS, eventually establishing NeuroSense.

NeuroSense is focused on creating combined therapeutic strategies, targeting multiple pertinent mechanisms involved in neurodegenerative diseases. Our research team and advisory board members are multidisciplinary professionals who have many years of experience with drug development and clinical programs. Their collective expertise and background enable us to move in a fast and efficient manner to achieve our goals.

To date, the company has completed an 18-month, double-blind, placebo-controlled, multi-national Phase 2b clinical trial in ALS with it’s lead therapeutic candidate, PrimeC. This breakthrough treatment has already demonstrated a significantly delay disease progression and impact on survival. The Company’s pipeline includes therapies for Alzheimer’s and Parkinson’s diseases.